Stephen J. Schuster, MD
Data for mosunetuzumab presented at the 2019 ASH Annual Meeting by lead investigator Stephen J. Schuster, MD, showed that the novel bispecific antibody induced durable responses in patients with highly refractory non-Hodgkin lymphomas (NHLs) enrolled in the phase I/Ib dose-escalation GO29781 study (NCT02500407).
Of note, complete remissions (CRs) were reached in 22.2% of patients who had previously received CAR T-cell therapy. Across all patients, the overall response rate was 37.1%, including a CR in 19.4% of patients.
In an interview with OncLive
, Schuster, who is director of the lymphoma program at Abramson Cancer Center at the University of Pennsylvania, discussed the promising findings and next steps for mosunetuzumab in patients with relapsed/refractory NHL.
... to read the full story